Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aselizumab, an antibody targeting L-Selectin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Talizumab, an antibody targeting IgE.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumiliximab, an antibody targeting FCER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galiximab, an antibody targeting B7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cantuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Adecatumumab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Urtoxazumab, an antibody targeting Shiga-like Toxin II.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Libivirumab, an antibody targeting Hepatitis B Virus Surface Antigen.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Exbivirumab, an antibody targeting Hepatitis B Surface Antigen.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zalutumumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Volociximab, an antibody targeting ITGA5B1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tucotuzumab, an antibody targeting EPCAM.